Device & Startup Companies
Startup created to develop catheter based technologies for replacing the mitral valve. Annulon has leveraged the large animal testing laboratory and the engineering/prototyping capabilities of the Gorman Cardiovascular Research Group (GCRG) to sequentially develop a sutureless mitral valve design, a minimally invasive off-pump mitral valve replacement technology and a totally percutaneously placed mitral valve. An extensive patent portfolio has been created to protect the related intellectual property. Annulon is currently in discussion with several device companies regarding the development of a strategic partnership to bring these devices to clinical practice.
Startup created to develop a catheter based retrieval system design to recovered malposition cardiovascular devices. During the past decade there has been an increasing number of devices placed by minimally invasive catheter based techniques. These devices include – atrial septal closure devices, intravascular stents, aortic valve replacements, pulmonic valve replacements as well as mitral and tricuspid valve repair and replacement devices. As the size and complexity of these endovascular devices increases so will the need for non-surgical retrieval techniques for malposition devices. Effective non-surgical retrieval options will further facilitate the expansion of catheter based devices to treat structural heart disease.
Startup created to develop minimally invasive and catheter base mechanical strategies for treating and preventing post infarction (post heart attack) heart failure. During the past decade the Gorman Cardiovascular Research Group has done extensive work demonstrating how restoration of left ventricular shape can improve post infarction heart failure. Cormend leverages the large animal testing facilities and engineering /prototyping capabilities of the GCRG to develop less invasive and ultimately catheter based technologies to achieve restoration of heart shape and function. A patent portfolio protects all related intellectual property.
Three dimension model of a left ventricular reshaping and assist device currently under development by the Gorman Cardiovascular Research Group. This device is designed to be placed on the epicardial surface over the left ventricular infarct region to optimally adjust geometry based on patient specific response with the ultimate goal of stimulating reverse remodeling. Device consists of a flexible outer shell, attachment platforms, and pneumatic artificial muscles (PAM). The flexible outer shell allows the device to bend to the 2D curvature of the epicardial surface and to contract in the circumferential direction. Attachment platforms are used to fasten the device to the epicardial surface using either suture or mechanical fasteners. PAMs provide the mechanical force to adjust ventricular circumferential and radial dimensions by shorting the device circumferentially and expanding radially. The device can also provide non-blood contacting direct epicardial assistance by cycling the PAMs in synchrony with the native ventricular contraction. This partial assist improves stroke volume and decreases the workload of the heart which could enhance myocardial function.
Startup created to develop biocompatible substances to alter the material properties of a myocardial infarct (area affected by a heart attack). In extensive preliminary work the Gorman Cardiovascular Research Group has demonstrated that stiffening the infarct early after a heart attack can prevent the progression to heart failure. Myostratum leverages the large animal testing facilities and material science capabilities of the GCRG to develop substances that can be delivered via catheters to the heart to prevent and treat heart failure. A patent portfolio protects all related intellectual property.
Startup created as a spinoff of Myostratum to combine the intellectual property of Myostratum with that of the New Zealand based company Kerablast. The goal of this company is to develop a keratin based material that can be delivered via coronary injection to alter the material properties of a myocardial infarction to prevent ventricular remodeling and heart failure.